HB1750, the Health Equity and Rare Disease Act of 2025 (HEARD Act of 2025), would direct the Department of Health and Human Services, the National Institutes of Health, the Centers for Disease Control and Prevention, the Food and Drug Administration, and related federal programs to expand research, education, and outreach focused on rare diseases and conditions that disproportionately affect minority populations. The bill creates a new NIH rare-diseases health equity framework, including a coordinating committee, a federal research plan, and requirements to study incidence, causes, screening, treatment, and public education efforts. It also calls for a broader federal plan to improve early detection, diagnosis, treatment, and quality of life for affected patients and families.
The bill further authorizes or directs multiple grant, scholarship, loan repayment, and training initiatives. These include grants for data collection and community outreach, physician and health professional training, mentoring programs, scholarships and loan repayment for clinicians serving rare-disease populations, and programs to increase minority representation in rare-disease research. It also requires reports to Congress on federal efforts, data gaps, clinical trial diversity, Medicare barriers, and tribal epidemiology activities, while encouraging culturally and linguistically appropriate awareness campaigns and tribal health research.
In practical terms, the bill would amend several sections of the Public Health Service Act and the Indian Health Care Improvement Act, and it would add new federal responsibilities for NIH, CDC, FDA, HRSA, and the Indian Health Service. It would not itself create a direct patient benefit program, but it would expand federal research, reporting, and grant-making authority and could influence how federal health agencies prioritize rare-disease work, especially for minority, Native American, and Tribal communities. It also touches Medicare by requiring a review of barriers affecting beneficiaries of color with rare diseases and telehealth access.
Because no committee transcripts or votes were provided, there is no recorded floor or committee sentiment to assess. Based on the bill text alone, the measure appears broadly supportive of health equity, rare-disease research, and workforce development, with an emphasis on underserved populations. The overall tone is policy-oriented and affirmative, rather than controversial on its face.
The main points of potential contention are likely to be administrative burden, federal spending, and whether the bill creates duplicative programs across NIH, CDC, FDA, and HHS. Some stakeholders may also question the feasibility of coordinating multiple agencies, the scope of reporting requirements, and how grant and scholarship funds would be allocated. Others may focus on whether the bill sufficiently addresses rare-disease patients generally, versus its narrower emphasis on minority populations and related health equity goals.
HB1750 would amend the Public Health Service Act and the Indian Health Care Improvement Act to add new federal programs, planning requirements, grant authorities, and reporting obligations related to rare diseases in minority populations. It would require NIH, CDC, FDA, HHS, and tribal health entities to coordinate research, data collection, education, workforce training, and public awareness efforts, and it would direct a Medicare review of barriers affecting beneficiaries of color with rare diseases. The bill would expand federal authority and likely increase administrative and programmatic activity across multiple health agencies and Indian health programs.
The bill’s likely areas of contention are funding, agency workload, and coordination across multiple federal entities. Critics may argue that the bill creates overlapping mandates for NIH, CDC, FDA, HRSA, and HHS, and that the reporting and planning requirements could be burdensome. There may also be debate over the bill’s focus on minority populations, whether it sufficiently addresses rare diseases more broadly, and how to prioritize limited research and workforce resources among competing public health needs.